sunpharma industries ltd. new1

7/27/2019 SunPharma Industries Ltd. New1

1/27

Group members - Group No.1

NAMES

KHUSHALI THAKORE

KHUSHALI JAIN

KHYATI PATEL

KONICA JAIN

KRUNAL MEHTA

ROLL NO.

10061

10062

10063

10064

10065


2/27


3/27

Introduction


4/27

Creating Value, Continuously

1983

Began with5 products

1993

First Research CentreSPARC, Baroda

1994

IPO - Rs. 550 Mnraised

1995

First APIPlant Panoli

1997

$7.5Mn investedin Caraco

2004

USD 350mnFCCB raised

2007

Demergerof innovative

R&D to SPARC

The performance continues

2010

5 Key operatingsubsidiaries8,000+ Employees

Invested Rs. 17 billionin Research

More than 50% of sales from international markets

Sun Pharma Today

83 10

19 Manufacturing facilitiesin 4 Continents

PART OF


5/27

Manufacturing LocationsPlants across four continents enables us to compete with a tight

handle on cost and time to market across the geographies

Jammu

Ahmednagar

Maduranthakam

BangladeshPlant

Sikkim Plant

Ameri

cas

Cranbury

Detroit

Bryan

Tennessee

Goinia(Brazil)

Iztapalapa(Mexico)

Tiszavasvari(Hungary)

Europe

API and Formulations API Formulations

Halol

Ankleshwar

Panoli

DadraSilvassa

Karkhadi

India


6/27

Vision, mission & values

Vision : To brand register in major markets of the

world.

Mission :

To lead globally in pharma sector.

To strengthen the market share & focus oncustomers needs.


7/27

REVENUE COMPOSITION

45%

30%12%

13%

India

Branded Generics

5 Year CAGR 22%

US Generics

5 Year CAGR 33%

APIs

5 Year CAGR 19%

International Branded

Generics (ex-US)

5 Year CAGR 43%

2009-10 Annual sales : Rs 40,761 million5 Year CAGR 26%


8/27

PHARMACEUTICAL MARKET

GLOBAL SCENARIO

INDIAN PHARMA MARKET


9/27

India Branded Generics :Strong Base

Market Share 3.7%

Leadership in chronic

segment;Top 3 in over 50% of

more than 500 brands

Neuro-Psychiatry

27%

Cardiology19%

Diabetology11%

Gastroenterology14%

Gynecology &

Urology- 7%

Musculo-Skeletal& Pain- 5%

Antiasthamatic &Antiallergic- 5%

Opthalmology- 4%Others8%

Therapywise Break-up


10/27

Mergers & acquisitionsYear Acquisition Country Rationale

2009Caraco acquired some products ofForests Inwood business

US Increased generic product offerings

2008 Acquired Chattem Chemicals, Inc. Tennessee, US Import registration with DEA, API Plantapproved by DEA in Tennessee, US

2005 Assets of Able labs New Jersey, US Dosage form plant (NJ, US) and IP

2005 Formulation plant in Bryan Ohio, US Dosage form plant (Ohio, US)

2005 Acquired ICN Hungary Hungary API and dosage form plant (Hungary)

2004 Womens Health Brands US Brands in womens health (US)

2004 Merged Phlox Pharma Baroda, India API Plant

2000Merged Pradeep DrugCompany Ltd (PDCL)

Chennai, India API Plant

1999 Merged Milmet Labs India Ophthalmology brands

1998 Brands from Natco India Respiratory brands

1997 Acquired Caraco Detroit, US Dosage form Plant

1997Merged Tamilnadu DadhaPharmaceuticals Ltd (TDPL)

Chennai, IndiaGynecology and oncology brands; APIand dosage form plant

1996 Acquired MJ Pharma Halol, IndiaDosage form plant (now USFDAapproved)

1996 Acquired Gujarat Lyka Ankleshwar, India API plant

1996 Bulk Drug plant from Knoll Pharma Ahmednagar,India

API plant (now USFDA approved)


11/27

Shareholding patternas on 31stjuly10

Mutual Funds 3%

Promoter and

Promoter

group

63%

Bodies Corporate 5%

Individuals and others 6%

Financial Inst / Banks 3%

FIIs / Foreign Banks

20%


12/27

FINANCE


13/27


14/27


15/27


16/27


17/27

SALES & PAT

0

10000

20000

30000

40000

50000

60000

70000

2005-2006 2006-2007 2007-2008 2008-2009 2009-2010

Figures

inmillion

Year

PAT

Sales


18/27

Profit ratio & ROI

0%

10%

20%

30%

40%

50%

60%

2005-2006 2006-2007 2007-2008 2008-2009 2009-2010

Valuein

Percentage

Year

NPAT

ROI


19/27

INVENTORY TURNOVER

0

1

2

3

4

5

6

7

8

2005-2006 2006-2007 2007-2008 2008-2009 2009-2010

N

o.oftimes

Year

InventoryTurnover


20/27

DEBT-EQUITY RATIO

0

0.2

0.4

0.6

0.8

1

1.2

1.4

2005-2006 2006-2007 2007-2008 2008-2009 2009-2010

Value

Year

DebtEquity


21/27

CURRENT RATIO

0

2

4

6

8

10

12

2005-2006 2006-2007 2007-2008 2008-2009 2009-2010

Value

Year

Current Ratio


22/27

EARNINGS PER SHARE

0

10

20

30

40

50

60

70

80

90

100

2005-2006 2006-2007 2007-2008 2008-2009 2009-2010

Rs.

Year


23/27

Reasons for growth

INDIAN HEALTH CARE OPPORTUNITY

CONCENTRATION OF CHRONIC

INTERNATIONAL MARKET

MERGERS AND ACQUISITIONS


24/27

Research & Development

Generic R&D spend around 8% of net

sales

Strong research teams in generics,

finished dosage development, biological

support, chemistry

2 R&D centers with about 600 scientists

Mumbai

Balancingthe risk

Medium term

Drug delivery systems

Immediate term

ANDA, DMF, Products for India

Baroda


25/27

Corporate Governance

Our philosophy on corporate governance

envisages working towards high levels of

transparency, accountability and consistent value

systems across all facets of operations

Committee chaired by Keki Mistry comprisesHasmukh Shah and

S. Mohanchand Dadha

Audit Committee

Accountability

Responsibilty

Fareness

Consistent Value


26/27

Corporatesocial responsibilty

Environmental issues

Handle waste

Minimize environment contamination

Reducing pollution


27/27

THANKYOU

sunpharma industries ltd. new1

Documents